Back to search

Article

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients

2022-03-13

Abstract excerpt

<h4>Background</h4> Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer but the study to prioritize effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic changes between patients with distinct response to neoadjuvant immunotherapy in non-small-cell lung cancer (NSCLC) for the derive of biomarkers with indicative capability in predicting ou...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
aaf55646-5a1e-55e9-92be-31311925cac4
DOI
10.1101/2022.03.12.22272306
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsDOI 10.1101/2022.03.12.22272306
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patientsSemantic proximity
Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysisSemantic proximity
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signaturesSemantic proximity
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.Semantic proximity
Somatic mutations in homologous recombination pathway predict favorable prognosis after immunotherapy across multiple cancer typesSemantic proximity
DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung CancerSemantic proximity
Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signaturesSemantic proximity
Multiomics analysis of homologous recombination deficiency across cancer types.Semantic proximity
Pan-cancer analysis of tumor mutational burden and homologous recombination DNA damage repair by targeted next-generation sequencingSemantic proximity
Molecular architecture of the tumor microenvironment caused by <i>BRCA1</i> and <i>BRCA2</i> somatic mutations in lung adenocarcinomaSemantic proximity
DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.Semantic proximity
Select a neighboring publication to make it the new centre.